for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acer Therapeutics Inc

ACER.OQ

Latest Trade

2.95USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

1.88

 - 

28.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.95
Open
--
Volume
--
3M AVG Volume
2.87
Today's High
--
Today's Low
--
52 Week High
28.23
52 Week Low
1.88
Shares Out (MIL)
10.10
Market Cap (MIL)
29.78
Forward P/E
-1.01
Dividend (Yield %)
--

Latest Developments

More

Acer Therapeutics Reports Second Quarter Loss Per Share $1.09

Acer Therapeutics Sees Charge Of About $1.5 Million Associated With Workforce Reduction In Q2 Of 2019.

Acer Therapeutics Reorganizes; Headcount Reduced To 19 Employees

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Acer Therapeutics Inc

Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Industry

Biotechnology & Drugs

Contact Info

One Gateway Center (300 Washington St.)

Suite 351

+1.302.4215753

https://acertx.com/

Key Stats

2.33 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-10.148

2017

-3.840

2018

-2.490

2019(E)

-2.913
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-150.15
Return on Equity (TTM)
-126.93

Latest News

Latest News

FDA declines to approve Acer Therapeutics' rare genetic disorder treatment

Acer Therapeutics Inc said on Tuesday the U.S. Food and Drug Administration declined to approve its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture, sending its shares plunging as much as 78%.

FDA declines to approve Acer Therapeutics' treatment for rare genetic disorder

Acer Therapeutics Inc said on Tuesday its treatment for a severe, rare genetic disorder that can cause blood vessels to fatally rupture was declined approval from the U.S. Food and Drug Administration.

BRIEF-Acer Therapeutics Q4 Loss Per Share $0.63

* ACER THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Acer Therapeutics Q3 loss per share $1.09

* Acer Therapeutics reports third quarter 2017 financial results and provides corporate update

BRIEF-Acer Therapeutics welcomes two new members to its board

* Acer Therapeutics welcomes two new members to its board of directors

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up